(Q46727594)

24 December 2017

title

Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer (English)

1 reference

24 December 2017

author name string

Avishay Sella

1

1 reference

24 December 2017

Amnon Zisman

2

1 reference

24 December 2017

Svetlana Kovel

3

1 reference

24 December 2017

Nirit Yarom

4

1 reference

24 December 2017

Dany Leibovici

5

1 reference

24 December 2017

Arie Lindner

6

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

24 December 2017

published in

Urology

1 reference

24 December 2017

volume

71

1 reference

24 December 2017

issue

2

1 reference

24 December 2017

page(s)

323-327

1 reference

24 December 2017

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

High-risk localized prostate cancer: a case for early chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Optimal two-stage designs for phase II clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Impact of positive surgical margins after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Radical prostatectomy for high-grade prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Management of locally advanced prostate cancer. 1. Staging, natural history, and results of radical surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: Analysis of freedom from psa failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Surgery with adjuvant irradiation in patients with pathologic stage C adenocarcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

Current indications for chemotherapy in prostate cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.08.060

10.1016/J.UROLOGY.2007.08.060

7 January 2021

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017